BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 26833127)

  • 21. MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.
    Qian Y; Galan-Cobo A; Guijarro I; Dang M; Molkentine D; Poteete A; Zhang F; Wang Q; Wang J; Parra E; Panda A; Fang J; Skoulidis F; Wistuba II; Verma S; Merghoub T; Wolchok JD; Wong KK; DeBerardinis RJ; Minna JD; Vokes NI; Meador CB; Gainor JF; Wang L; Reuben A; Heymach JV
    Cancer Cell; 2023 Jul; 41(7):1363-1380.e7. PubMed ID: 37327788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer.
    Long LL; Ma SC; Guo ZQ; Zhang YP; Fan Z; Liu LJ; Liu L; Han DD; Leng MX; Wang J; Guo XJ; Tan JL; Cai XT; Lin Y; Pan X; Wu DH; Bai X; Dong ZY
    Cancer Res; 2023 Feb; 83(4):568-581. PubMed ID: 36512628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression.
    Xu C; Fillmore CM; Koyama S; Wu H; Zhao Y; Chen Z; Herter-Sprie GS; Akbay EA; Tchaicha JH; Altabef A; Reibel JB; Walton Z; Ji H; Watanabe H; Jänne PA; Castrillon DH; Rustgi AK; Bass AJ; Freeman GJ; Padera RF; Dranoff G; Hammerman PS; Kim CF; Wong KK
    Cancer Cell; 2014 May; 25(5):590-604. PubMed ID: 24794706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional analysis of LKB1/STK11 mutants and two aberrant isoforms found in Peutz-Jeghers Syndrome patients.
    Boudeau J; Kieloch A; Alessi DR; Stella A; Guanti G; Resta N
    Hum Mutat; 2003 Feb; 21(2):172. PubMed ID: 12552571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.
    Akbay EA; Koyama S; Liu Y; Dries R; Bufe LE; Silkes M; Alam MM; Magee DM; Jones R; Jinushi M; Kulkarni M; Carretero J; Wang X; Warner-Hatten T; Cavanaugh JD; Osa A; Kumanogoh A; Freeman GJ; Awad MM; Christiani DC; Bueno R; Hammerman PS; Dranoff G; Wong KK
    J Thorac Oncol; 2017 Aug; 12(8):1268-1279. PubMed ID: 28483607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.
    Sanchez-Cespedes M; Parrella P; Esteller M; Nomoto S; Trink B; Engles JM; Westra WH; Herman JG; Sidransky D
    Cancer Res; 2002 Jul; 62(13):3659-62. PubMed ID: 12097271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-17C-mediated innate inflammation decreases the response to PD-1 blockade in a model of Kras-driven lung cancer.
    Ritzmann F; Jungnickel C; Vella G; Kamyschnikow A; Herr C; Li D; Menger MM; Angenendt A; Hoth M; Lis A; Bals R; Beisswenger C
    Sci Rep; 2019 Jul; 9(1):10353. PubMed ID: 31316109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin.
    Shackelford DB; Abt E; Gerken L; Vasquez DS; Seki A; Leblanc M; Wei L; Fishbein MC; Czernin J; Mischel PS; Shaw RJ
    Cancer Cell; 2013 Feb; 23(2):143-58. PubMed ID: 23352126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. STK11 loss leads to YAP1-mediated transcriptional activation in human KRAS-driven lung adenocarcinoma cell lines.
    Lenahan SM; Sarausky HM; Deming P; Seward DJ
    Cancer Gene Ther; 2024 Jan; 31(1):1-8. PubMed ID: 37968341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lkb1 deletion in murine B lymphocytes promotes cell death and cancer.
    Souroullas GP; Fedoriw Y; Staudt LM; Sharpless NE
    Exp Hematol; 2017 Jul; 51():63-70.e1. PubMed ID: 28435024
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Biton J; Mansuet-Lupo A; Pécuchet N; Alifano M; Ouakrim H; Arrondeau J; Boudou-Rouquette P; Goldwasser F; Leroy K; Goc J; Wislez M; Germain C; Laurent-Puig P; Dieu-Nosjean MC; Cremer I; Herbst R; Blons H; Damotte D
    Clin Cancer Res; 2018 Nov; 24(22):5710-5723. PubMed ID: 29764856
    [No Abstract]   [Full Text] [Related]  

  • 33. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 34. LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment.
    Peña CG; Nakada Y; Saatcioglu HD; Aloisio GM; Cuevas I; Zhang S; Miller DS; Lea JS; Wong KK; DeBerardinis RJ; Amelio AL; Brekken RA; Castrillon DH
    J Clin Invest; 2015 Nov; 125(11):4063-76. PubMed ID: 26413869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation.
    Granado-Martínez P; Garcia-Ortega S; González-Sánchez E; McGrail K; Selgas R; Grueso J; Gil R; Naldaiz-Gastesi N; Rhodes AC; Hernandez-Losa J; Ferrer B; Canals F; Villanueva J; Méndez O; Espinosa-Gil S; Lizcano JM; Muñoz-Couselo E; García-Patos V; Recio JA
    Commun Biol; 2020 Jul; 3(1):366. PubMed ID: 32647375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1.
    Nagaraj AS; Lahtela J; Hemmes A; Pellinen T; Blom S; Devlin JR; Salmenkivi K; Kallioniemi O; Mäyränpää MI; Närhi K; Verschuren EW
    Cell Rep; 2017 Jan; 18(3):673-684. PubMed ID: 28099846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer.
    Bonanno L; Zulato E; Pavan A; Attili I; Pasello G; Conte P; Indraccolo S
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30995715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence.
    Mitchell KG; Parra ER; Zhang J; Nelson DB; Corsini EM; Villalobos P; Moran CA; Skoulidis F; Wistuba II; Fujimoto J; Roth JA; Antonoff MB;
    Ann Thorac Surg; 2020 Oct; 110(4):1131-1138. PubMed ID: 32442617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
    Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
    Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.
    Kitajima S; Ivanova E; Guo S; Yoshida R; Campisi M; Sundararaman SK; Tange S; Mitsuishi Y; Thai TC; Masuda S; Piel BP; Sholl LM; Kirschmeier PT; Paweletz CP; Watanabe H; Yajima M; Barbie DA
    Cancer Discov; 2019 Jan; 9(1):34-45. PubMed ID: 30297358
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.